User login
Key clinical point: Survival was not significantly different in patients with metastatic colorectal cancer (mCRC) younger than 50 years vs. those aged 50 years or older.
Major finding: The median overall survival (adjusted hazard ratio [aHR], 0.98; P = .78) and progression-free survival (aHR, 1.02; P = .67) were not significantly different in younger- vs. older-onset patients with mCRC.
Study details: This study included 2,326 patients with mCRC from CALGB/SWOG 80405 phase 3 trial, of which 514 patients younger than 50 years at study entry were included in the younger CRC cohort.
Disclosures: The study was funded by the National Cancer Institute of the National Institutes of Health and in part by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some of the authors reported receiving research funding/honoraria from and/or consulting/advising for various sources.
Source: Lipsyc-Sharf M et al. J Natl Cancer Inst. 2021 Oct 12. doi: 10.1093/jnci/djab200.
Key clinical point: Survival was not significantly different in patients with metastatic colorectal cancer (mCRC) younger than 50 years vs. those aged 50 years or older.
Major finding: The median overall survival (adjusted hazard ratio [aHR], 0.98; P = .78) and progression-free survival (aHR, 1.02; P = .67) were not significantly different in younger- vs. older-onset patients with mCRC.
Study details: This study included 2,326 patients with mCRC from CALGB/SWOG 80405 phase 3 trial, of which 514 patients younger than 50 years at study entry were included in the younger CRC cohort.
Disclosures: The study was funded by the National Cancer Institute of the National Institutes of Health and in part by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some of the authors reported receiving research funding/honoraria from and/or consulting/advising for various sources.
Source: Lipsyc-Sharf M et al. J Natl Cancer Inst. 2021 Oct 12. doi: 10.1093/jnci/djab200.
Key clinical point: Survival was not significantly different in patients with metastatic colorectal cancer (mCRC) younger than 50 years vs. those aged 50 years or older.
Major finding: The median overall survival (adjusted hazard ratio [aHR], 0.98; P = .78) and progression-free survival (aHR, 1.02; P = .67) were not significantly different in younger- vs. older-onset patients with mCRC.
Study details: This study included 2,326 patients with mCRC from CALGB/SWOG 80405 phase 3 trial, of which 514 patients younger than 50 years at study entry were included in the younger CRC cohort.
Disclosures: The study was funded by the National Cancer Institute of the National Institutes of Health and in part by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some of the authors reported receiving research funding/honoraria from and/or consulting/advising for various sources.
Source: Lipsyc-Sharf M et al. J Natl Cancer Inst. 2021 Oct 12. doi: 10.1093/jnci/djab200.